Condition (MeSH)
Parotid Diseases
ClinicalTrials.gov lists 111 trials for Parotid Diseases or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 24.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 of the 111 trials are tagged with Parotid Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Parotid Diseases trials start? (28)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 3 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 5 |
| 2020 | 6 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 2 |
Showing 10 of 28 earlier years.
No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 74 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Parotid Diseases trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 39 |
| Phase 4 | 16 |
| Not applicable | 15 |
| Observational | 22 |
How many Parotid Diseases trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 7 |
| Active, not recruiting | 3 |
| Completed | 74 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Parotid Diseases trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 24 |
| Merck Sharp & Dohme LLC | 19 |
| Sanofi Pasteur, a Sanofi Company | 5 |
| Sinovac (Dalian) Vaccine Technology Co., Ltd. | 3 |
| Fondation Ophtalmologique Adolphe de Rothschild | 2 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Parotid Diseases? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| VARIVAX | 6 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| M-M-R II | 6 |
| Priorix | 6 |
| ProQuad | 6 |
| Havrix+Havrix | 5 |
| Comparator: M-M-R II | 5 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Parotid Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Gastroenteritis | 148 | 24 |
| Pneumonia | 109 | 22 |
| Febrile convulsion | 106 | 21 |
| Bronchiolitis | 80 | 16 |
| Bronchitis | 66 | 9 |
Showing 5 of 10 adverse events.
Which publications cover Parotid Diseases? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study. | JAMA otolaryngology-- head & neck surgery | 2017 | Yes |
| Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis. | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery | 2016 | Yes |
| Histological characteristics following a long-term nitrate-rich diet in miniature pigs with parotid atrophy. | International journal of clinical and experimental pathology | 2015 | Yes |
| Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. | Oral diseases | 2006 | Yes |
| Postoperative salivary fistula: therapeutic action of octreotide. | Surgery | 1995 | Yes |
Showing 5 of 7 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.